# US 2013/0157879 A1 · Biomarker dact1 for gastric cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157879 A1
- Document ID: US20130157879A1
- Status: Published application
- Kind: A1
- Application number: 13/328,785
- Filed: 2011-12-16
- Published: 2013-06-20
- Earliest claimed: 2011-12-16
- Assignees: The Chinese University of Hong Kong
- Inventors: Jun YU; Joseph Jao Yiu Sung; Shiyan Wang
- Web page: https://patentgrep.com/patent/US20130157879A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- G01N 33/5753: of the stomach or small intestine
- C12Q 2600/154: Methylation markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the DACT1 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing DACT1 gene expression or activity.

## Claims

### Claim 1

A method for detecting gastric cancer in a subject, comprising the steps of:
(a) measuring expression level of DACT1 in a sample taken from the subject, and
(b) comparing the expression level obtained in step (a) with a standard control,
wherein a decrease in the expression level of DACT1 when compared with the standard control indicates the subject having gastric cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is a stomach mucosa sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the expression level of DACT1 is DACT1 protein level.

### Claim 4 (depends on 1)

The method of claim 1, wherein the expression level of DACT1 is DACT1 mRNA level.

### Claim 5 (depends on 3)

The method of claim 3, wherein step (a) comprises an immunoassay using an antibody that specifically binds the DACT1 protein.

### Claim 6 (depends on 5)

The method of claim 5, wherein step (a) comprises a Western Blot analysis.

### Claim 7 (depends on 1)

The method of claim 1, wherein step (a) comprises mass spectrometry or hybridization to a microarray, fluorescence probe, or molecular beacon.

### Claim 8 (depends on 4)

The method of claim 4, wherein step (a) comprises an amplification reaction.

### Claim at position 9

-16. (canceled)

### Claim 17

A method for detecting gastric cancer in a subject, comprising the steps of:
(a) treating a sample taken from the subject with an agent that differentially modifies methylated and unmethylated DNA; and
(b) determining whether each CpG in a CpG-containing genomic sequence is methylated or unmethylated, wherein the CpG-containing genomic sequence is at least a segment of SEQ ID NO:1 or 6 and comprising at least one CpG,
wherein presence of one methylated CpG in the CpG-containing genomic sequence indicates the subject having gastric cancer.

### Claim 18 (depends on 17)

The method of claim 17, wherein the CpG-containing genomic sequence comprising two or more CpG, and wherein at least 50% of all CpG being methylated indicates the subject having gastric cancer.

### Claim at position 12

-22. (canceled)

### Claim 23 (depends on 17)

The method of claim 17, wherein CpG-containing genomic sequence is SEQ ID NO:6, and wherein at least 5 of all CpG being methylated indicates the subject having gastric cancer.

### Claim 24 (depends on 17)

The method of claim 17, wherein the sample is a stomach mucosa sample.

### Claim 25 (depends on 17)

The method of claim 17, when the subject is indicated as having gastric cancer, further comprising repeating steps (a) and (b) at a later time using the sample type of sample from the subject, wherein an increase in the number of methylated CpG at the later time as compared to the number of methylated CpG determined from the original step (b) indicates a worsening of gastric cancer, and a decrease indicates an improvement of gastric cancer.

### Claim 26 (depends on 17)

The method of claim 17, wherein the agent that differentially modifies methylated DNA and unmethylated DNA is an enzyme that preferentially cleaves methylated DNA, an enzyme that preferentially cleaves unmethylated DNA, or a bisulfate.

### Claim 27 (depends on 17)

The method of claim 17, wherein step (b) comprises an amplification reaction.

### Claim 28

(canceled)

### Claim 29

A kit for detecting gastric cancer in a subject, comprising (1) a standard control that provides an average amount of DACT1 protein or DACT1 mRNA; and (2) an agent that specifically and quantitatively identifies DACT1 protein or DACT1 mRNA.

### Claim 30 (depends on 29)

The kit of claim 29, wherein the agent is an antibody that specifically binds the DACT1 protein.

### Claim 31 (depends on 29)

The kit of claim 29, wherein the agent is a polynucleotide probe that hybridizes with the DACT1 mRNA.

### Claim at position 22

-35. (canceled)

### Claim 36

A method for inhibiting growth of a gastric cancer cell, comprising contacting the gastric cancer cell with an effective amount of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:5 or a nucleic acid comprising a polynucleotide sequence encoding SEQ ID NO:5.

### Claim at position 24

-40. (canceled)

### Claim 41

An isolated nucleic acid having the nucleotide sequence at least 95% identical to a segment of about 20-100 contiguous nucleotides of SEQ ID NO:1, 2, 3, 4, or 6 or complement thereof.

### Claim at position 26

-43. (canceled)
